First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial.

Levy, Sonja; Verbeek, Wieke H M; Eskens, Ferry A L M; van den Berg, José G; de Groot, Derk Jan A; van Leerdam, Monique E; Tesselaar, Margot E T

Levy, Sonja; Verbeek, Wieke H M; Eskens, Ferry A L M; van den Berg, José G; de Groot, Derk Jan A; van Leerdam, Monique E; Tesselaar, Margot E T.

Afiliación

Levy S; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Verbeek WHM; Department of Gastroenterological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Eskens FALM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
van den Berg JG; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
de Groot DJA; Department of Medical Oncology, University Medical Centre Groningen, Groningen, The Netherlands.
van Leerdam ME; Department of Gastroenterological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Tesselaar MET; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Ther Adv Med Oncol ; 14: 17588359221077088, 2022.

Article en En | MEDLINE | ID: mdl-35251315

Palabras clave

cisplatin; everolimus; neuroendocrine carcinoma

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Ther Adv Med Oncol Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google